BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation needle hand immobile. In slant culture transfer, the inoculation needle will be first treated with the aseptic technique by flaming. The slant culture cap is then removed and secured using the needle hand. Flaming the open end of the slant culture will prevent contamination and the formation of aerosols. Transfer happens once the tip of the inoculation needle comes into contact with the agar surface of the slant culture. The inoculation needle should not move in the process. The agar slant culture will be moved up to the needle to prevent jostling of the needle. Once the transfer is complete from